|
| 37715730 | Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial. | Neuro Oncol | 2024 |
| 37944912 | Pediatric low-grade glioma: State-of-the-art and ongoing challenges. | Neuro Oncol | 2024 |
| 37526549 | Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). | Neuro Oncol | 2023 |
| 36335802 | The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. | Neoplasia | 2023 |
| 37738646 | Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation. | Neuro Oncol | 2023 |
| 37046770 | Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B. | | 2023 |
| 37534382 | Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors. | Pediatr Blood Cancer | 2023 |
| 35210278 | ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. | | 2022 |
| 35489353 | Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group. | Lancet Oncol | 2022 |
| 36335782 | Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36056180 | Nervous system (NS) Tumors in Cancer Predisposition Syndromes. | | 2022 |
| 35788692 | MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. | Neuro Oncol | 2022 |
| 35544730 | Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care. | JCO Precis Oncol | 2022 |
| 35977349 | Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. | JCO Precis Oncol | 2022 |
| 34990779 | A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. | Int J Radiat Oncol Biol Phys | 2022 |
| 35307742 | Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. | Neuro Oncol | 2022 |
| 35218656 | Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. | Neuro Oncol | 2022 |
| 34850169 | Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study. | Neuro Oncol | 2022 |
| 34591650 | Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. | Journal of Clinical Oncology | 2021 |
| 34168987 | Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. | Front Oncol | 2021 |
| 33631016 | A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. | Neuro Oncol | 2021 |
| 33583506 | Neonatal Central Nervous System Tumors. | Clinics in Perinatology | 2021 |
| 33354735 | Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. | Clinical Pharmacokinetics | 2021 |
| 33025730 | Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. | Pediatr Blood Cancer | 2021 |
| 33278109 | Advances in the classification and treatment of pediatric brain tumors. | Current Opinion in Pediatrics | 2021 |
| 32502457 | Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. | Lancet Oncol | 2020 |
| 32187454 | Pineoblastoma in children less than six years of age: The Head Start I, II, and III experience. | Pediatr Blood Cancer | 2020 |
| 32241771 | Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. | AJNR Am J Neuroradiol | 2020 |
| 32055852 | Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. | Neuro Oncol | 2020 |
| 32289265 | The "Risk" in Pediatric Low-Grade Glioma. | Cancer Cell | 2020 |
| 31545689 | Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. | J Clin Oncol | 2019 |
| 30531227 | Management of pediatric low-grade glioma. | Current Opinion in Pediatrics | 2019 |
| 31287992 | A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. | Cancer Cell | 2019 |
| 30670636 | Transcriptional repressor REST drives lineage stage-specific chromatin compaction at <i>Ptch1</i> and increases AKT activation in a mouse model of medulloblastoma. | Sci Signal | 2019 |
| 30997512 | Improved neuropsychological outcomes following proton therapy relative to X-ray therapy for pediatric brain tumor patients. | Neuro Oncol | 2019 |
| 31151904 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. | Lancet Oncol | 2019 |
| 29741745 | Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. | Neuro Oncol | 2018 |
| 29016845 | Pediatric low-grade gliomas: next biologically driven steps. | Neuro Oncol | 2018 |
| 27683733 | Pediatric low-grade gliomas: implications of the biologic era. | Neuro Oncol | 2017 |
| 28733870 | Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. | J Neurooncol | 2017 |
| 28689260 | Extended diffusion weighted magnetic resonance imaging with two-compartment and anomalous diffusion models for differentiation of low-grade and high-grade brain tumors in pediatric patients. | Neuroradiology | 2017 |
| 28339824 | A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. | Neuro Oncol | 2017 |
| 28326681 | Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. | CPT: Pharmacometrics and Systems Pharmacology | 2017 |
| 28879377 | Erratum to: Extended diffusion weighted magnetic resonance imaging with two-compartment and anomalous diffusion models for differentiation of low-grade and high-grade brain tumors in pediatric patients. | Neuroradiology | 2017 |
| 29435175 | REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. | Oncotarget | 2017 |
| 28011926 | Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. | Neuro Oncol | 2017 |
| 27510726 | Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. | Neuro Oncol | 2017 |
| 27622066 | Improving vaccine efficacy against malignant glioma. | Oncoimmunology | 2016 |
| 27187113 | Severe Radiation Necrosis Successfully Treated With Bevacizumab in an Infant with Low-Grade Glioma and Tumor-Associated Intractable Trigeminal Neuralgia. | Pediatr Blood Cancer | 2016 |
| 27425592 | The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation. | Oncogene | 2016 |